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ABSTRACT 
CHRISTINA KARAMINI: Biopolymer matrix enhances bone regeneration in rat critical size  
skull defects. 
(Under the direction of Dr. Lyndon F Cooper) 
 
Reducing the need for harvesting autologous bone is a major goal of current research.  A 
recently developed collagen/dextran hygrogel scaffold (E-matrixTM) may offer osteoinductive 
advantages as a biologic polymer for bone repair. This scaffold, by mimicking embryonic 
extracellular matrix, could promote osteogenesis in the absence of osseoinductive agents.  
8.9mm craniotomy defects were created in the parietal bone of 23 Sprague-Dawley rats. In a 
randomized manner, implants (Collagen only, Collagen/E matrix, Collagen/BMP) were 
placed onto the defect.  Healing was permitted for 2, 4 or 6 weeks. At these timelines BMP 
treated defects showed good bone repair (26.20%, 42.60% and 22.12% bone fill, 
respectively). EmatrixTM defects showed equal bone repair at 4 and 6 weeks (40.21 and 
22.12% respectively), but reduced bone at 2 weeks (5.08%). Bone repair was incomplete in 
Collage and saline treated defects. EmatrixTM supported bone repair of critical sized defects.  
The mechanism of action requires additional investigation. 
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INTRODUCTION 
 
The field of bone regeneration is rapidly evolving, and the use of osteogenic substances 
delivered to the wound site by means of constructs is one of the most promising methods to 
expedite new bone formation.  The construct delivered to the site is impregnated 
preoperatively with a substance to enhance cellular and matrix functions and interactions, 
and have biocompatible and biomimetic properties close to the natural tissues.  Our study 
will evaluate a new biopolymer as the matrix for the implanted constructs.   
 
The use of vertebrate animal models for evaluating the healing of bone defects and for the 
testing of materials and methods for improving the repair of bone is a logical, established, 
and accepted procedure that closely resembles human clinical settings.  We have selected the 
rat calvaria model for our experiments.  The reason behind it lies on the fact that blood 
supply is only present at the base of skull at the area of muscle attachment into the skull. The 
critical size defect in the calvarium is a particularly good model (Sikavitsas et al. 2003) since 
it provides an excellent challenge to the tested material due to the lack of a primary nutrient 
artery, and its relative low marrow content. For these reasons the skull defect is considered 
the most severe bone implant test (Sikavitsas et al. 2003).  The earliest scientific mention of a 
critical size skull defect was in 1889 by N. Senn who evaluated the healing process of 
trephined bone in dogs after implanting them with antiseptic decalcified bovine bone.  
Subsequently, the concept of “critical size defect” as currently understood has been defined 
by Schmitz and Hollinger (1986) as: “the smallest size intraosseous wound that will not heal 
spontaneously during the lifetime of the animal.”  This definition should be applied only to 
those defects created in adult animals, and healing is understood as development of new 
bone.  In the rat model, the defect should be a 0.8cm in diameter perforation through the 
calvarium (Sirola, 1960). Using this site is advantageous since no stabilization of the scaffold 
is required because the cranial site does not bear significant mechanical loads (Gysin et al. 
2002). 
 
Based on a recent literature review (Lutolf et al. 2003, Sikavitsas et al. 2005, Gysin et al. 
2002), the rat model is a commonly employed model.  We will utilize this model and try to 
follow standardized procedures in order to minimize the number and risk to the animal 
subjects, and to be able to compare our results with those obtained in the past by other 
institutions. In addition the significance of hBMP-2 will be tested in promoting osteogenesis 
as stated in studies by Reddi (1998). 
 
Specific aim   
As a first step in defining the role of this novel biomimetic scaffold (E-matrix), the 
osteoinductive efficacy will be tested using the rat calvaria critical size defect model.  E-
matrix will be delivered to 8.9 mm diameter calvaria defects in a collagen scaffold 
(Duragen®) and bone repair will be measured by histomorphometry after 2, 4 and 6 weeks of 
healing.  hBMP-2/ collagen gel and empty defects will serve as positive and negative 
controls, respectively.  
 
Clinical Significance
In the future, bone regeneration can be applied clinically where lack in bone mass can 
compromise or prohibit optimum treatment or when prognosis of final treatment is enhanced. 
Thus functional replacements for damaged or pathologic tissues can be made (Alsberg & 
Mooney, 2001) for example in recreating missing osseous structures (vertical bone loss), 
correcting craniofacial deformities and enhancing bone/tooth or bone/implant functionality 
and long-term stability (Earthman et al. 2003). 
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 Bone regeneration and repair is of growing importance in dentistry.  Reducing the need for 
harvesting autologous bone through the development of new biomaterials containing both 
osteoconductive and osteoinductive properties is a major goal of current research.  Different 
approaches are now available and the majority of materials require the use of a scaffold or 
space filling material to direct bone formation in the targeted defect or extraskeleletal 
location.  The various materials used as a scaffold for bone repair include autogenous bone, 
allogenic and xenogenic bone, and synthetic biomaterials.  Recent investigations using 
synthetic resorbable polymers suggest an advantage of rapid biomaterial resorption, however, 
most of these synthetic polymers are not osteoconductive, osteoinductive nor osteogenic.  
Biologic polymers, (e.g. collagens) are often used as scaffolds for BMP-mediated bone 
repair.  Other biologic polymer formulations may offer advantages of cell adhesion and 
stimulation for osteocondutive or osteoinductive bone repair.     
 A recently developed collagen / dextran hygrogel may offer osteoinductive 
advantages as a biologic polymer scaffold for bone repair (E-matrixTM).  This matrix may 
serve as a biomimetic of the immature / embryonic extracellular matrix and, as such, offer 
insoluble signals to mesenchymal stem cells for tissue repair / regeneration.  Preliminary 
studies in this laboratory suggest this hygrogel is able to support bone repair.    The goal of 
this project was to define the osteogenic potential of E-matrix for repair of bone using 
temporal evaluation of bone healing in the rat calvaria critical size defect model.   
 
HYPOTHESIS 
If osseous wound healing is controlled by mesenchymal cell / scaffold interactions, then a 
collagen/ proteoglycan scaffold capable of mimicking embryonic extracellular matrix will 
promote osteogenesis in the absence of osseoinductive agents.    
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LITERATURE REVIEW 
 
TISSUE ENGINEERING 
 This project relies on the principle of tissue engineering, which according to Pollok & 
Vacanti (1996) is the application of the principles and methods of engineering and the life 
sciences to the fundamental understanding of structure/function relationships in normal and 
pathological tissues and the development of biological substitutes to restore, maintain or 
improve function. Tissue engineering provides the capability of creating specific, man-made 
tissues known as neo-organs that can overcome the problems associated with tissue 
transplantation (Langer & Vacanti, 1993). Tissue engineering approaches combine three 
main factors: reparative cells, signaling molecules and scaffold carriers (Reddi, 2000). In our 
project we tested a novel material (E-matrixTM), a porcine collagenous matrix and its ability 
to induce endogenous and exogenous osteogenesis. 
Osseous wound healing involves the recruitment of mesenchymal stem cells to perform the 
molecular tasks of bone regeneration. The initial matrix onto which these cells emerge is a 
key effector of bone formation or repair. Numerous materials are suggested as 
osteoconductive materials that support bone formation.  A novel tissue-derived polymeric 
material has recently been used for cutaneous wound repair and is based on biomimicry of 
embryonic extracellular matrices.  A collagen / proteoglycan scaffold (E-matrixTM) has been 
used to promote healing of diabetic cutaneous ulcers.  It is possible that this scaffold contains 
important molecular cues that enable stem cell function and support bone tissue repair. 
 
Overall a tissue-engineered implant designed to restore or modify the function of a tissue or 
organ is usually composed of a combination of biocompatible materials and biological 
components of the tissue (Anderson, 1998).  
Repair vs Regeneration  
The repair of bone, as well as of any tissue, is a rapid process which has been selected 
through evolution to allow an animal to get up and move out of danger quickly. The 
wounded tissue is made avascular and thus becomes sealed off from the rest of the body 
(Davies JE, 2000, p.441).  This ensures that micro-organism contamination does not spread 
throughout the body. The key to successful bone repair is the presence of high titers of 
mesenchymal stem cells (MCSs) that differentiate into a bridging cartilage mass in the 
avescular sector the connective tissue. 
However, the regeneration of bone, is a much slower process than that of repair. In particular 
the regeneration at a cortical bone site of discontinuity, a thin monolayer of bone must form 
first at the inner or outer limit of the existing bone. This is followed by the formation of a 
layer of osteoblasts that produce thin sheets of osteoid which is densely mineralized. 
Vascular tissue always follows the layer of osteoblasts. The mineralization events always 
take place at a fixed distance from the secreting osteoblasts to ensure the separation of 
osteoid formation from mineral deposition.  
Unfortunately, we are still uncertain of the key factors controlling the formation of the whets 
of osteoblasts and therefore unable to proceed with the design of tissue-engineered cortical 
bone that follows the regeneration pathway. Thus, we must focus on the repair pathway for 
the purposes of bone engineering. 
 
Several key factors have been identified in the repair of bone (Davies JE, 2000, p.442): 
1. Well-defined boundaries of the defect must be fully occupied by the implant material 
to inhibit dysfunctional fibrosis. 
2. MSCs must migrate into or be placed within these boundaries. 
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3. These boundaries must be occupied by a cell-delivery vehicle that either is resorbed 
or becomes functionally integrated into the new structure. 
4. Adequate vascular supply must be present and must aggressively communicate with 
the entire length and depth of the defect for the supply of nutrients and chemotactic/ 
osteogenic factors. 
5. Lastly, osteogenic bioactive factors which target and affect MSCs and their lineage 
descendants as well as the vascular network must be present. 
 
 
SCAFFOLDS/ DELIVERY VEHICLES
As mentioned above, the use of delivery vehicles is essential in the bone engineering process. 
Approximately over 500,000 bone grafts are performed in the United States to repair or 
regenerate diseased or missing bone. Although autologous bone grafts have been long 
established as the “gold standard” for such procedure they are fraught with a number of 
complications mainly including chronic pain and physiologic impairment of the donor site, 
infection, hemorrhage, nerve damage and cosmetic deformity. In addition the use of allograft 
materials, as an alternative material for bone reconstruction, has been problematic with 
regard to their immunogenicity, compromised biomechanical and physiological properties as 
well as potentially limited supply. Thus, researchers have been focusing into engineering 
synthetic, three-dimensional bone scaffolds made from polymeric materials onto which cells 
or growth factors can be incorporated to induce normal bone formation (Hollinger et al., 
2005, p.150). 
 
These scaffolds should encompass the characteristics of biofunctional and multiphasic 
properties of delivery vehicles. Such scaffolds should house or attract progenitor cells 
capable of progressing down the entire chondrogenic lineage to the end-stage phenotype, 
calcified hypertrophic cartilage. In other words, they must organize, in a defined volume with 
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precise boundaries, the differentiation of cartilage that can be rapidly replaced by 
endochondral bone. This is the first phase in the multiphasic process of bone repair. 
Secondly, the ideal vehicle should exhibit bioactivity unique to the first phase and preferably 
dissolve to initiate and contribute to the second phase. (Davies JE, 2000, p.457) 
 
Biodegradable scaffolds offer the possibility of replacing osseous tissue and overcoming 
problems such as infection and device dislocation which are associated with permanent 
implants (Davies JE, 2000, p.454) 
Further to these inherent biological properties, scaffolds need to fulfill the following physical 
properties based on the mechanical loading demands of the defect site: 
 
1. The scaffold should be easy to handle in the preparation and implementation of the 
implant materials 
2. It should be highly porous to allow rapid vascular ingrowth into the defect area. 
3. It should maintain the space for differentiated and specialized extracellular matrices 
and structural components. The material should be strong enough to withstand physiological 
stresses, yet, a lack of sufficient mechanical stimulation may result in poor tissue 
regeneration and/or bone resorption around the implant. (Davies JE, 2000, p.455). 
4. It should be easily adjustable/ moldable to fit the defect or surgical site. 
5. It must exhibit a reproducible and controlled breakdown or dissolution process in 
every insertion site.  Since the scaffold’s mechanical strength usually decreases as it 
degrades, the degradation rate should be coupled to the rate of tissue regeneration in order to 
maintain the structural integrity of the construct (Davies JE, 2000, p.455) 
 
Thus, such properties must not be affected by the host’s response or the implantation site. 
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Further to the properties mentioned above, the delivery vehicle must be biocompatible and 
thus fail to evoke an extreme adverse inflammatory or immune response once implanted 
(Davies JE, 2000, p.456). An important point is that the scaffold’s biocompatibility, as far as 
the material’s chemical and physical structure and physical morphology is concerned, can be 
affected by synthesis or processing techniques.  
Another important aspect in the manufacturing of scaffolds is the method of sterilization, 
which must not interfere with the bioactivity of the material, or significantly alter its 
chemical composition and consequently its biocompatibility or degradation properties 
(Davies JE, 2000, p.456).  
 
Application of scaffolds  
Tissue growth
Tissue growth involves cellular migration from the host tissue into the scaffold to form new 
tissue. In this case, the scaffold only acts as a substrate to encourage migration and 
proliferation of the desired cell types. It has been shown that both poly(propylene fumarate) 
(PPF) and poly(DL-lactic-co-glycolic acid (PLGA) are able to attract osteoblasts into the 
defect site (Davies JE, 2000, p.456). 
 
Cell transplantation
In this application, the delivery vehicle should not only demonstrate migration of native cells 
into the defect but also support proliferation and differentiated function of seeded cells. For 
the purposes of bone regeneration, stromal osteoblasts and osteoblasts from the donor are 
seed onto the scaffold and expanded in culture prior to the transplantation of the construct to 
the patient. Both PPF and PLGA have been shown to support in vivo these functions (Davies 
JE, 2000, p.457) 
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Delivery of bioactive molecules
Examples of these molecules include bone morphogenetic proteins (BMPs), transforming 
growth factor beta-1 (TGF-β1) and hormones (e.g. oestrogen, thyroxin). Controlled delivery 
of these factors to aid in bone regeneration is often desired, eventually leading to the 
incorporation of the bioactive molecules into the implantable scaffolds. Loading procedures 
can either involve binding of the molecules to the polymer during the  scaffold processing or 
loading onto bioresorbable nanoparticles that become entrapped within the scaffold. (Davies 
JE, 2000, p.457) 
 
Prevascularisation
This application can be used to allow the ingrowth of vascular tissue (either fibrovascular or 
periosteal) before cell seeding. Such application is considered since the rate of 
vascularisation is often insufficient to prevent cell death within the implanted construct. Bone 
defects created after tumour removal particular benefit from prevascularisation because the 
recipient tissue bed is commonly undermined in its ability to support vascularisation due to 
abnormal local bone physiology and the necrotic effects of locally delivered radiotherapy 
(Davies JE, 2000, p.457). In this case, polymer scaffolds are implanted onto a periosteal site 
remote to the defect and allowed to form vascularised bone prior their re-implantation to the 
defect site (Davies JE, 2000, p.457). 
 
Scaffold materials 
Preformed
They are the most widely investigated types of scaffolds and have been associated with cell 
transplantation applications. These delivery vehicles are more biocompatible since residual 
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toxic chemical can be removed by leaching them in water after processing them. Cells can be 
seeded onto these scaffolds and cultures in vitro prior to the construct’s implantation. In this 
way the production of large sections of tissue is possible prior to implantation. Examples of 
such scaffolds are PLA, PGA, PLGA, and PPF. Other less extensively tested polymers 
include pseudo-poly(amino acids), poly(carbonates), poly(acrylates), poly (phosphates), 
poly(phosphazenes) and poly(anhydrates) (Davies JE, Bone Engineering, p.458). 
The most extensively used group of polymeric scaffolds belong to the family of poly(α-
hydroxy acids) which include poly(lactic acid) (PLA) and poly(glycolic acid) (PGA) and 
their copolymers. PLA exist in two enantiomeric isomers of lactide (D and L). PLA degrades 
to lactic acid which is further metabolized yielding CO2 and water. The copolymerization of 
the two enantiomeric forms yields PDLLA which is clinically applied in craniofacial 
fixations.  
PGA is a highly insoluble polymer and its solvent, hexafluoroisopropanol is highly toxic. For 
this reason PGA is used as a copolymer with PLA. When degraded to glycolic acid it is 
metabolized in the body. 
The copolymer of PLA and PGA is poly(lactic-co-glycolic acid) (PLGA) and it has been 
extensively studied in tissue engineering projects. The copolymer was initially introduced as 
“LactoSorb” manufactured by Lorenz Surgical Inc. It has been shown to completely resorb in 
12 months (Hollinger et al., 2005, p.152) and has been used in pediatric craniofacial 
reconstruction. 
 
Injectable 
Such polymers can more easily fill defects of various sizes and shapes, requiring minimal 
surgical intervention. Liquid and gel scaffolds which belong to this category function to 
physically entrap cells destined to be implanted in the defect site. However, such scaffolds 
lack in mechanical strength and therefore cannot be used in load-bearing defects such as 
those in orthopaedic cases. Nevertheless they are amenable to polymerization and cross-
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linking in situ should additional strength be required. Alternatively it has been reported that 
PPF is often combined with ceramic particles such as β-TCP, calcium carbonate or calcium 
phosphate for use in orthopaedics (Davies JE, 2000,  p.459). Another advantage of these 
scaffolds is the presence of large number of interconnected pores that promote bone 
ingrowth. 
Curing of these scaffolds is initiated by chemical means or via the use of light. Cross linking 
agents include methyl-methacrylate (MMA). Also the degradation and mechanical properties  
of these materials can be achieved via photopolymerisation with particles or different linear 
polymers within them, resulting in interpenetrating polymer networks. 
 
HYDROGELS
This type of scaffolds permit the retention of large amount of water on the polymer without 
causing it to dissolve. They share many characteristics with biological tissues, namely their 
permeability to small molecules and their low interfacial tension. Although hydrogels do not 
possess increased mechanical strength to support loaded skeletal structures, they provide a 
matrix for accelerated tissue formation which will in turn provide mechanical integrity. 
Alginate, pluronics, chitosan and fibrin glue are some examples of hydrogel scaffolds. 
In addition to the aforementioned properties of scaffolds, hydrogels in particular should 
encompass the following characteristics according to Temenoff & Mikos (2000): 
1. Biocompatibility and non-toxic degradation products 
2. Sufficient mechanical strength for the intended applications 
3. Ability to promote tissue formation 
4. Sterilizability to prevent infection 
5. Be able to polymerize on a clinically acceptable time scale with a minimal 
temperature change 
6. Promote ease of handling by the surgeon 
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Cells can be encapsulated during hydrogel formation and the latter can be fabricated in situ 
within the defect site in the body. The porosity of these scaffolds can be modulated by 
altering the cross-linking density (Elisseeff et al., 2005). 
Chen et al., (2003) looked into the efficacy of an injectable form of hydrogel to induce bone 
tissue. They utilized a temperature-depended polymerizing polyethylene oxide hydrogel as a 
vehicle to deliver bone marrow mesenchymal cells in rats. After an observation period of 2 
months they found that areas of mature endochondral bone exhibiting trabeculation and 
abundance of bone matrix and osteocytes enclosed in lacunae. Although this method 
eliminates the invasive procedure of conventional bone grafting it poses the inherent problem 
of confining the injectable bone and fine molding into the desired contours at the defect site. 
 
In an in vitro study by Mikos’ group (Payne et al., 2002) it was shown that bone marrow 
stromal cells exhibited much higher viability, proliferation and phenotypic expression when 
they were encapsulating in actively crosslinking PPF composites rather than their non- 
encapsulated counterparts in a test period of 28 days. 
Alginate, a polysaccharide, is extracted from seaweed that forms an ionic gel in the presence 
of divalent cations such as calcium.  It has been extensively studied in vitro and in vivo as a 
scaffold for cartilage replacement and engineering, in the craniofacial region. 
To address tissue engineering of osteochondral tissue, a multilayered hydrogel system was 
developed (Elisseeff et al., 2005). This system allow for distinct cell types to be co-cultured 
in 3 dimensional systems.  
Bosnakovski and co-workers (2006) showed the osteogenic and chondrogenic effect of type I 
collagen hydrogel in combination with TGF-β1. Yet, they found that collagen type II was the 
most favorable one for expressing chondrogenic phenotype as it resulted in the upregulation 
of chondrogenic genes and synthesis of type II collagen and GAG. 
Trojani et al., (2006) in an in vivo study examined the osteogenic effect of self-hardening Si-
hydroxypropylmethylcellulose (HPMC) in conjunction with HA/TCP when it was injected 
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subcutaneously (SC) and intramuscularly (IM). They found that after 8 weeks of 
implantation mineralized woven bone was present markedly invaded by numerous 
osteoblasts. Increased amount of active osteoclasts attached to the HA/TCP particles and 
small vessels being homogenously distributed in the entire area of the implant was also 
observed histologically. The lack of fibrous encapsulation of these particles proved good 
osseointegration of the composite into the surrounding tissues. Si-HPMC is a hydrogel with 
hardening time of 10 minutes which allows for manipulation in in vitro applications and 
injection in in vivo settings. The hydrophilic polymeric phase of the hydrogel makes the 
material injectable and when hardened it serves as a space-holder to prevent granule packing 
and providing for homogenous delivery of cells into the recipient site. 
Overall this model provided evidence for a novel method of osteoinduction with promising 
result for possible future application. 
 
Scaffold fabrication 
The main goal in scaffold fabrication is to introduce porosity in a three dimensional network 
which is essential in bone regenerative procedures. Some of the most important techniques 
are summarized below. 
 
Particulate-leaching
Porogen leaching was patented by Mikos and his co-workers in 1996 (Hollinger et al. 2005, 
p.159). In this technique water soluble particles (salt, sugars or polymer spheres) are 
dispersed in a matrix comprising of the scaffold material dissolved in an organic solvent. 
This process can yield the following: 
1. “skin” of nonporous polymer at the surface 
2. non-homogeneous dispersion of pores 
3. lack of inner connectivity of the pores, and 
4. remaining porogen within the scaffold after porogen leaching. 
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Emulsion Freeze-drying 
In this technique a homogenized emulsion of the polymer solvent solution and water is 
created. The solvent and the water are then removed by freeze-drying after the mixture is 
rapidly quenched in liquid nitrogen. The advantages of this technique include the ability to 
control the pore sizes from 15 to 200 microns and the ability to obtain porosity in excess of 
90%. 
 
Phase separation 
This technique involves the demixing of homogeneous polymer/ solvent solution into both 
polymer-rich and polymer-poor phases. Unlike freeze-drying method it does not involve the 
homogenization of the mixture. A modification procedure, termed as “coarsening effect”, 
was applied to the original technique of phase-separation to increase the pore size from 1-20 
μm to greater than 100μm. A clear disadvantage is the use of dioxane as a solvent, which is a 
suspected carcinogen. 
 
3D Printing 
A complex 3-D structure is constructed by a polymer powder packed with salt particles. This 
structure is subjected to a solvent selectively applied. Subsequently the polymer/ salt 
composites are submerged into water to dissolve the salt particles resulting in porous devices 
with micropores (45-150μm). This is a relatively new method. 
 
Gas foaming
CO2 is used in this method to create porosity which allows for the application of growth 
factors onto the scaffold. Unfortunately in this technique the pores are not interconnected. 
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Polymer Microspheres and Growth Factor delivery 
The properties and importance of the different growth factors in bone engineering will be 
reviewed in the upcoming chapter. In this section, however, emphasis is placed on how these 
important molecules can be locally delivered and administered to the grafted sites. 
Adsorption of growth factors onto the polymer scaffolds’ surface is one method of delivery 
(Hollinger et al., 2005, p.160). Yet, this method does not allow for the precise and controlled 
release of the growth factor over time onto the target site. For this reason researchers looked 
into the encapsulation of growth factors within polymeric microspheres which are then 
incorporated within the scaffold. 
 
Polymer microspheres are hollow capsules and are commonly fabricated from either 
synthetic or naturally occurring polymers, such as PLGA and gelatin respectively. 
Techniques for their fabrication include water/oil/water emulsion or oil/water emulsion or 
spray-drying. The encapsulated growth factors are released in a controlled manner over a 
period of time once the polymer begins to degrade. 
 
Hu et al., (2001) reported controlled release of a model protein (bovine serum albumin, BSA) 
after it became encapsulated within PLGA microsphere that had been coated with poly(vinyl 
alcohol). An additional study by Meese et al., in 2002 (Hollinger et al., 2005, p.161) 
confirmed the feasibility of this approach. 
Ambrosio and co-workers in 2001 (Hollinger et al., 2005, p.161) developed a novel 
technique involving sintering of PLGA microspheres to form a porous scaffold. However, 
this method precludes the incorporation of growth factors into these carriers due to the use of 
heat in this procedure. 
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In 2001 Richardson et al., (Hollinger et al., 2005, p.161) described the fabrication and 
evaluation of a poplymer scaffold that delivered two growth factors for bone regeneration in 
the context of therapeutic angiogenesis. In this study vascular endothelial growth factor 
(VEGF)-165 and platelet-derived growth factor (PDGF)-BB – growth factors with distinct 
kinetics – were incorporated into a single polymer scaffold. The project showed the rapid 
formation of a mature vascular network and the researchers emphasized not only the success 
of such a scaffold but also the necessity for delivery of multiple growth factors for significant 
clinical application compared to the limited application of single growth factor delivery. 
 
SIGNALING MOLECULES 
 
Growth Factors 
They are hormones that are best characterised as activity modulators. They can either 
stimulate or inhibit cellular proliferation, differentiation, migration, adhesion, apoptosis and 
gene expression (Hollinger et al., 2005, p.126). 
Insulin-like growth factors (IGFs), bone morphogenetic proteins (BMPs), fibroblast growth 
factors (FGFs) and vascular endothelial growth factors (VEGFs) are some of  the secreted 
soluble growth factors that play an important role in wound healing by regulating 
chemoattraction, mitogenesis and differentiation (Hollinger et al., 2005, p.126). The spatial 
localization of growth factors drives the temporal sequence of wound healing. (Hollinger et 
al., 2005, p.126). Yet, one of the major obstacles for tissue engineering of bone is to control 
the spatial gradients of wound healing factors. 
 
Bone Morphogenetic Proteins (BMPs)
Bone morphogenetic proteins are members of the TGF-β superfamily. BMPs were 
discovered by Marshall R. Urist in 1965.  Since then 15 individual BMPs have been 
identified (Hollinger et al., 2005, p.130) and several including BMP – 2, -4, -5, -6, and -7 
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have been shown to be osteoconductive (Hollinger et al., 2005, p.130). These BMPs 
stimulate differentiation of mesenchymal stem cells to an osteochondroblastic lineage. 
(Hollinger et al., 2005, p.130). 
BMP-2 promotes apoptosis in primary human calvarial osteoblasts (Hollinger et al., 2005, 
p.130). BMP-3 is the most abundant BMP in demineralised bone and it may act as an 
important modulator of the activity of other osteogenic BMPs in vivo. In 2003, Campisi et al. 
(Hollinger et al., 2005, p.130) showed that BMP-2 and -4 were highly expressed in 
osteoblastic cells during distraction in a rabbit mandibular distraction model. They suggested 
that BMP could participate in the transduction of mechanical stimuli into biochemical 
response. In particular rhBMP-2 stimulates the activity of alkaline phosphatase in bone 
marrow stromal cells (Thies et al., 1992). 
The osteoinductive properties of injectable BMPs into polymeric scaffolds was suggested by 
Saito N. in 2003, (Hollinger et al., 2005, p.131) and in particular rh-BMP-2 was found to 
successfully regenerate bone in critical-size defects in rats, rabbits, sheep and dogs (Hollinger 
et al., 2005, p.131). Yet, the application of BMPs in phylogenetically higher species remain 
questionable due to the superphysiological doses of rh-BMP-2 used (0.75 & 1.5mg/mL) in 
spinal fusion model in monkeys by Boden and co-workers in 1998 (Hollinger et al., 2005, 
p.131).  Administration of BMPs in the amount of milligrams have raised serious concerns 
regarding the unpredictability of potentially sinister sequelae (Hollinger et al., 2005, p.131). 
Suggested therapeutic dosages of rhBMPs are presented on the following table: 
 
SPECIES DOSAGE 
Human 1.5 – 3.5 mg (10-3 of gram) 
Rats 10 μg  (10-5 of gram) 
Cell culture/ embryonic development 1pg (10-12 of gram) 
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Table 2.1 Relative rhBMP dosage in different species. The 10-x values in the parentheses provide an idea of the 
concentrations of the chemicals necessary to induce a therapeutic result. 
 
In order to initiate intracellular signaling, as a dimmer BMP binds to a complex of type I & II 
transmembrane receptors, consequently inducing a phosphorylation reaction and ultimately 
upregulation of bone-specific regulation genes. 
 
Tissue Growth Factor Beta (TGF-β)
This growth factor superfamily is predominately found in bone, platelets and cartilage and 
their main function involves growth, differentiation and extracellular matrix synthesis. TGF-
β receptors have been found in increased numbers on chondrocytes and osteoblasts which has 
lead researches to associate TGF-β with bone development and its repair process at all stages 
(Hollinger et al., 2005, p.129). 
In 2003, Zhang and co-workers (Hollinger et al., 2005, p.130) showed that TGF- β1 
enhances mineralization of human osteoblasts on implant materials and it has been well-
documented as a potent chondrogenic factor, integral to chondrocyte and matrix homeostasis 
(Bosnakovski et al., 2006). In vivo experiments suggest that it might enhance the activity of 
BMP-2 (Hollinger et al., 2005, p.130). However, such results relied on the use of 
superphysiological doses of TGF- β1 preparation which raises concern about potential 
unwanted side effects in in vivo models. Overall the action of TGF- β, which initiates 
signaling similar to that of BMPs, is not well understood and it is speculated that it might not 
function alone as a bioactive factor in bone engineering.  
 
Fibroblast Growth Factor (FGF) 
FGFs, have been shown to produce promising results in promoting bone formation and 
enhancing the development of blood vessels. Marie et al., in 2002 (Hollinger et al., 2005, 
p.131) showed that FGF-2, FGFR-2 and BMP-2 are key factors in promoting proliferation, 
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differentiation and apoptosis in in vitro study on human calvaria osteoblasts. FGF-2 which is 
expressed in osteoblasts appears to be more potent than FGF-1 (Hollinger et al., 2005, 
p.132). 
Insulin-Like Growth Factors (ILGF) 
Insulin-like growth factors –I and –II (IGF) are produced by bone cells, stored in bone matrix 
and stimulate bone cell DNA synthesis and type I collagen production.  In vitro and in vivo 
experiments have shown that IGFs stimulate osteoblast proliferation and differentiation 
(Hollinger et al., 2005, p.132). These growth factors act on osteoblasts inducing them to 
increase collagen production. They also inhibit collagen degradation by decreasing 
collagenase synthesis (Hollinger et al., 2005, p.132). Although IGF-II is the most abundant 
growth factor in bone it is IGF-I that appears to be the most potent of the two (Hollinger et 
al., 2005, p.132), with the latter being isolated from healing fractures in rats and humans 
(Hollinger et al., 2005, p.132). This local synthesis of IGF-I by osteoblasts appears to be 
important for bone remodeling. In particular this growth factor has been associated with 
intramembranous bone defect repair (Hollinger et al., 2005, p.133). When mesenchymal cells 
were transduced by IGF-I they preferentially migrated to the fracture site and repopulated the 
bone marrow, accelerating fracture healing (Hollinger et al., 2005, p.133). Overall, 
researchers have established the mitogenic effect of IGFs on bone marrow stromal cells 
although it appears that their effect on the differentiation depend on the maturation stage of 
these cells (Hollinger et al., 2005, p.133). 
 
Platelet-Derived Growth Factors (PDGF) 
In vitro studies have shown that PDGF, which is secreted by platelets during the early stage 
of fracture healing, is mitogenic for osteoblasts. However its therapeutic impact is yet to be 
established (Hollinger et al., 2005, p.133). 
 
Vascular Endothelial Growth Factors (VEGF) 
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VGEFs are endogenously produced and promote angiogenesis, vasodilatation and increased 
permeability in vivo (Hollinger et al., 2005, p.134). These factors also induce endothelial cell 
proliferation, promote cell migration and inhibit apoptosis. 
IN VIVO MODELS
Experimental animal models have been extensively utilized to test the efficacy and evaluate 
at a preclinical stage the appropriateness of novel structures, compounds and methodologies 
particularly in the field of bone engineering. 
A number of general factors must be considered prior to choosing an animal model for such 
studies. These include the following: 
1. Animal model appropriateness  
2. Potential extrapolation to the clinical setting 
3. Genetic homogeneity of the specific animal model 
4. Available data on skeletal anatomy, bone physiology and biomechanical properties   
    and osseous wound healing 
5. Cost and availability of the model 
6. Application of the results across species 
7. Ease and adaptability of the model to experimental and laboratory manipulations 
8. Ecological considerations 
9. Ethical and societal implications 
 
Specifically to bone engineering, the “goodness-of-fit” of a particular animal model will 
depend on the strategy employed to augment bony tissue. The levels of hypothesis testing are 
summarized on the following table. (Hollinger et al., 2005, p.219) 
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Bone Tissue Engineering Paradigms 
Level of Hypothesis 
testing 
Osteoconduction Osteoinduction Osteogenic Cell 
Transplantation 
Basic bone cell biology 
models 
In vitro or in vivo 
manipulation of 
cell or tissue 
response to 
trauma using 
mechanical or 
environmental 
factors 
In vitro or in vivo 
manipulation of 
cell or tissue 
response to 
trauma using 
growth factors, 
cytokines, or 
genes 
IN vitro or in vivo 
manipulation of autologous 
or isohistogenic donor 
osteogenic cell response to 
host bone trauma 
General clinical models Repair of critical-
sized defects 
using a passive 
mechanical 
scaffold 
Repair of 
critical-sized 
defects using 
resorbable 
scaffolds 
seeded with 
growth factors, 
cytokines, or 
genes 
Repair of critical-sized 
defects using resorbable 
scaffolds seeded with 
osteoblatsts or stem cells 
Specific clinical models Repair of bony 
defects in specific 
clinical conditions 
(e.g. periodontitis, 
diabetes, cleft 
palate, 
osteoporosis, etc.) 
using a passive 
mechanical 
scaffold 
Repair of bony 
defects in 
specific clinical 
conditions (e.g. 
periodontitis, 
diabetes, cleft 
palate, 
osteoporosis, 
etc.) using 
resorbable 
scaffolds 
seeded with 
growth factors, 
cytokines or 
genes. 
Repair of bony defects in 
specific clinical conditions 
(e.g. periodontitis, diabetes, 
cleft palate, osteoporosis, 
etc.) using resorbable 
scaffolds seeded with 
osteoblasts or stem cells 
Table 2.2 Levels of Hypothesis testing in bone tissue engineering paradigms (Hollinger , Bone Tissue 
Engineering, p.219) 
 
The animal models that have been used in the above levels of hypothesis in bone engineering 
include rodents (mice, rats, Guinea pigs, rabbits), dogs, sheep, goat, pig and monkeys. 
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Animal models for bone engineering of Critical-sized defects (CSDs) 
One of the most important parameters in establishing the regenerative and osseo-inductive 
potential of osteogenic material is to apply them in defect areas where bone cannot be formed 
in adequate quantities to cover the entire size of the defect. The development of such a defect 
site is subject to the principle of Critical-Size Defect. Schmitz and Hollinger (1986) first 
defined a CSD as the “smallest size intraosseous defect in a particular bone and species of 
animal that will not heal spontaneously during the lifetime of the animal”.  
The anticipated physiologic response from the healing by secondary intention of a CSD is to 
histologically observe the formation of bony islands within the defect which hare joined by a 
characteristic fibrous connective tissue. This physiological state is known as bony non-union 
or fibrous union. More recently Hollinger and Kleinschmidt (1990) distinguished between a 
bony non-union from a CSD as a percentage of bone formed within the defect. They defined 
a CSD an area that “has less than 10% bone formation throughout its entire volume and any 
greater quantity of bone together with fibrous tissue comprises a bony non-union”. 
Developmentally the calvaria arise exclusively from intramembranous ossification. It has 
relatively limited vascular supply, poor healing properties and a biological inertness similar 
to that of long bone (Schmitz & Hollinger, 1986). The same group of workers indicated that 
in a period of 4 weeks even 3mm diameter defects in Sparague-Dawley rats had failed to heal 
completely.  
Overall trephine calvaria CSDs tend to be more predictable in size and reproducible than 
CSDs in long bones (Davies, 2000).  
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MATERIALS AND METHODS 
 
 
We obtained IACUC approval for our protocol and our laboratory facilities were approved 
by DLAM. 
 
ANIMALS
 
A total of 23 male, 5 month old rats (Sprague-Dawley) were used for this experiment. The 
animals were purchased from Harlan, Inc., (Indianapolis, IN). The animals were individually 
housed in plastic cages in a monitored environment (22 oC, 12:12 hr light cycle). They had 
ad libidum access to drinking water and a standard laboratory rat food pellet diet. 
 
SURGICAL PROCEDURE
 
Anesthesia was induced presurgically by intraperitoneal injection of ketamine/ xyalazine (40-
80 mg/kg; 5-20mg/kg respectively). The toe-pinch and the eye reflexes were used to monitor 
adequate level of anesthesia during the surgical procedure. The animals were positioned in 
sternal recumbency and monitored for respiration rate, and toe-pinch and eye reflex 
throughout and after the procedure as a way to ensure an appropriate level of anesthesia. 
Immediately before surgery each animal was given a subcutaneous injection of 
buprenorphine (0.15 mg/kg; Henry Schein, Melville, NY) for post-operative analgesia, and 
an intraperitoneal injection of 5ml of normal saline (0.9% NaCl; Henry Schein) for sensible 
and insensible fluid losses during the operative and recovery period. The conjunctiva was 
protected with the application of antibiotic ointment (“Perlube”). The incision site and wound 
area were shaved using an electric shaver and prepared with Betadine® scrub and 70% 
isopropanol. Using aseptic technique, a midline skin incision from the mid-nasal bone area to 
the posterior nuchal line was made and the underlying periosteum was incised and dissected. 
A trephine bur, with internal diameter of 8.0 mm and external diameter 8.9 mm, attached to a 
rotating slow-speed dental handpiece was used to create an 8.9 mm diameter defect in the 
bone. The dura was carefully guarded to avoid perforation and damage to the mid-sagittal 
blood vessels. The drilling site was under constant irrigation with a mixture of normal saline 
and lidocaine/ epinephrine in equal parts to minimize bleeding. Once the bone defect was 
prepared and the animal was stable, the implants were set in place. The implants were precut 
(diameter 8.0mm x 2.0mm thickness) absorbable collagen scaffold (Duragen®). At this point, 
sterilized test scaffold were saturated/ soak-loaded with either 1-2 drops of sterile 0.9% saline 
or an E-Matrix™ solution, or rhBMP-2 solution (5μg/ml) and placed in the defect. The 
surgical wound was closed by approximating the overlying tissues and suturing in layers with 
resorbable 5-0 Vicryl sutures (Ethicon, Somerville, NJ). Then, the animals were individually 
housed at room temperature and observed until they ambulated and did not show any visible 
signs of distress. After that, they were transferred to cages and were given access to water 
and food ad libidum. Approximately 8 hours after surgery each animal was given another 
subcutaneous injection of buprenorphine for post-operative analgesia. 24 hours after the 
surgery, each animal was given a subcutaneous injection of ketoprofen (5mg/kg; Henry 
Schein) in order to provide long-term analgesia. The animals were monitored daily for signs 
of complications related to surgery or illness. The animals were euthanized by CO2 inhalation 
2, 4 and 6 weeks after surgery. After euthanasia with CO2, perfusion fixation was performed 
using 10% formalin and the craniotomy sites were recovered. After debriding of soft tissue, 
harvested tissues were placed in 10% formalin. The periosteum was maintained intact on the 
samples. For each of the timelines tested the animals were distributed as follows: 
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 Test groups # of subjects Implant materials Defect 
    
Control 2 collagen & saline 
Positive control 3* collagen & rhBMP-2 
Test 3 collagen & E-matrix™ 
8.9mm    
diameter on 
calvarium 
* data available from only 2 subjects in the 2 week group 
Table 3.1 Distribution of animals in experimental groups according to tested periods. 
 
The study was conducted in non-blinded standards, as the surgical examiners were also 
involved in the histological analysis of the specimens. 
 
RADIOGRAPHIC ANALYSIS 
Radiographs of the rat calvaria gross samples were obtained to demonstrate defect size and 
the amount of mineralized bone within the defects. Standardized digital radiographic images 
were obtained using a dental radiographic unit (Gendex). Each of the specimens was rinsed 
with sterile water and excess fluid was removed. The specimens were individually positioned 
on a digital image receptor (27x36mm) at right angles to the source of the beam and were 
exposed to (66kVp, 8mA for 0.06 seconds). Densitometric tracing of the radiographs was 
used to estimate bone fill. The mean grey value (MGV) was calculated for each radiograph. 
 
HISTOMORPHOMETRY
Excised samples were decalcified and bisected along a line parallel to the sagittal suture. The 
specimens were processed for regular histology. All paraffin-embedded specimens were 
sectioned at 5μm and the sections stained with hematoxylin and eosin (H&E).  Using “Image 
J” software, the total defect and bone areas were measured. Only the areas of mineralized 
bone matrix and areas of osteoid were included. Areas of trabeculation were excluded. Those 
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two parameters and the area occupied by voids were measured in each of the three 
histological steps and the values averaged to obtain the specimen values. Individual specimen 
values were averaged to obtain group means and calculated deviations for defect, bone and 
void areas in mm2. Group means and standard deviations were calculated for the percentage 
of the defect area occupied by bone in the microradiographs and the histological sections and 
for the percentage of the defect area occupied by voids in the histological sections. Goldner’s 
trichrome staining was carried out on select slides for quantification of the osteoid production 
within the critical size defects. 
 
Additional calvaria sections were further stained with Goldner’s Trichrome Method. Stains 
were purchased from Electron Microscopy Sciences Inc. Once the paraffin sections were 
available they were treated and stained according to the following guidelines: 
1. Deparafinise at 60.1oC in block heater for 30 minutes. 
2. Decerated in Xylene, twice for 2 minutes each time. they were then placed in absolute 
alcohol for 5 minutes each; 95% alcohol, 2 changes, 2 minutes each; then rinsed with 
distilled water. These steps were carried out by a dedicated apparatus (Slide Moat, 
Boekel, Boekel Scientific) in our oral pathology lab. 
3. Mordant in Bouin’s Fluid solution for 1 hour at 56oC until formalin fixed. 
4. Cool and wash in running tap water until yellow color disappeared. 
5. Rinsed in distilled water. 
6. Slides placed in Weigert’s Solution for 10 minutes 
7. Washed in running tap water for 10 minutes. 
8. Rinsed in distilled water. 
9. Stained in Ponceau Acid Fuchsin for 5 minutes. 
10. Washed in Acetic Acid, 1%. 
11. Placed in Phosphomolybdic Acid-Orange G solution until collagen was decolorized. 
12. Rinsed in Acetic Acid, 1% for 30 seconds 
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13. Stain in Light Green Stock Solution for 5 minutes. 
14. Rinsed in Acetic Acid, 1% for 5 minutes. 
15. Section were blotted but not allowed to dry. 
16. Dipped quickly in absolute alcohol 
17. Slides were dehydrated in 95% alcohol and absolute alcohol 3 changes each. Clear in 
distilled water, 3 changes. These steps, too, were carried out in the Slide Moat 
apparatus. 
18. Coverglass was mounted onto stained slides (coverslipping) once coverslip medium, 
(Permount) was applied (refractive index of 1.48-1.56) 
 
The staining results were interpreted according to their color as follows: 
Brownish black – nuclear chromatin 
Bright red –  cytoplasm  
Orange –   erythrocytes 
Red –   muscle, osteoid 
Green –   collagen, mineralized mature bone 
 
 
STATISTICAL ANALYSIS
Our sample size (8 animals per timeline) was not adequate to warrant statistical analysis 
using ANOVA and t-testing. Thus, we restricted our analysis to descriptive statistics only 
using percentages of absolute values. 
 
Studies measuring the delivery of BMP to calvaria defects measured a mean difference (δ) 
between a sham treatment and BMP loaded group of 1.51mm2, with a standard deviation (σ) 
of 1.34 mm2 for the experimental group. Using 9 animals per treatment group ensures that 
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with a 0.05 Type 1 probability error (α) the experimental power is 88%. We used one-way 
ANOVA to evaluate  
1. whether there are any differences between different treatment groups within each 
time line 
2. if for each treatment group there is any difference in the amount of bone produced 
between the 2nd, 4th and 6th week time lines. 
Where the p value in either of the above experiments indicated statistical difference (<0.05), 
a t-test was run to determine between which treatment groups (in one timeline) or which 
timelines (within a specific treatment group) the difference was significant for. 
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RESULTS 
 
HISTOLOGY  
Representative histological slides only were selected to demonstrate the progress of bone 
regeneration associated with each treatment group in the second, fourth and sixth week of 
assessment. 
 
In all specimens the lamellar pattern of growth is defining the borders of the CSD. At two 
weeks out from the surgery date there are negligible areas of osteoid present in the control 
week group that can be found adjacent to the periosteum. The latter seems to be delineating 
the outer side of the defect. Most of the scaffold material (DuraGen®) appears to be 
relatively intact. 
 
Figure 1.  Control group (DuraGen® and saline) at 2 weeks. 
 
 
 In the E-matrixTM group, there is also very little evidence of bone formation (Fig.2). The 
central area of the defect on this slide is associated with an inflammatory reaction consistent 
with the presence of the suture material (Vicryl, 4/0). 
 
Figure 2.  E-matrixTM and DuraGen® at 2 weeks. 
 
On the contrary osteoid formed fairly uniformly along the length of the defect in the rhBMP-
2 group (Fig.3). The collagen scaffold (DuraGen®) has not yet been fully resorbed 
occupying a thin layer along the entire length of the defect on the brain surface of the defect. 
 
Figure 3. DuraGen® and rhBMP-2 at 2 weeks. 
 
 30
At four weeks some osteoid has started forming in the central portion of this section in the 
control (Fig.4). Again, an inflammatory reaction is associated with the area of the suture 
material on the right side of the specimen in Figure.4.  
Figure 4. Control (DuraGen® and saline) at 4 weeks. 
 
The section in Figure 5, which is representative of the bone repair pattern for the E-matrixTM 
group at 4 weeks, has not been taken through the widest portion of the defect but rather 
closer to the edges. Almost the entire length and half the thickness of the CSD is occupied by 
osteoid. Portion of this increased volume of bone might be due to the proximity to the 
periphery of the defect where osteogenesis commences during the reparative process. 
 
 
 
 
 
 
 
 
Figure 5. E-matrixTM and DuraGen® at 4 weeks. 
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In the rhBMP-2 group we can see a considerable amount of osteoid formation predominately 
peripherally. The central portion of the specimen in Figure 6 is associated with two features. 
The first is the inflammatory area related to the suture material. The second is the thinning of 
the thickness of the specimen right of the inflammatory portion. This could be either an 
artifact due to bending of the tissue slice when prior to its placement on the slide or 
stretching of the tissue when slices were being obtained. Another explanation is the presence 
of a tear in the collagen sponge (DuraGen®) during the implantation period. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  DuraGen® and rhBMP-2 at 4 weeks. 
 
 
At six weeks in the control group (Fig.7) some osteoid has been sparsely formed along the 
CSD but most of the area is occupied by loose fibrous connective tissue.   
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Figure 7. Control (DuraGen® and saline) at 6 weeks. 
 
E-matrixTM induced a considerable amount of bone formation (Fig.8), which is thicker 
towards the edges of the CSD but lacks, however, in continuity along the entire length of the 
defect. In contrast to earlier timelines, the bone appears to have matured and become more 
organized. The presentation is consistent with that of woven bone. DuraGen® has completely 
resorbed. 
 
 
Figure 8. E-matrixTM and DuraGen® at 6 weeks. 
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In the rhBMP-2 group we also appreciated lack of continuity of the newly formed bone 
which too has the appearance of woven bone. There is some evidence of DuraGen® still 
being present on the brain side of the defect. 
 
Figure 9.  DuraGen® and rhBMP-2. 
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IMAGE J ANALYSIS 
We used the “Image J” software for our histomorphometrical analysis. The periosteum was 
preserved on the specimens, thus providing the boundaries of our CSDs. Only the areas of 
woven bone and osteoid were accounted for. Any voids that could even be part of the 
trabecular bone pattern were excluded. “Image J” analysis was applied to individual slides. 
Specimen values were averaged to obtain group means and calculated deviations for defect, 
bone and void areas in mm2. Group means and percentages were calculated for the 
percentage of the defect area occupied by bone in the microradiographs and the histological 
sections and for the percentage of the defect area occupied by voids in the histological 
sections. Table 4.1 presents the average percentage of area of the defect occupied by newly 
formed bone. For the complete account of defect area per each slide refer to Tables A.2, A.4 
and A.6 in the appendix section. 
 
Treatment 2 week  4 week 6 week 
Collagen and saline 2.12 10.01 8.55 
Collagen and BMP 26.20 42.61 22.12 
Collagen and EmatrixTM 5.08 40.21 22.12 
Table 4.1 Average Percent (%) of bone formed within the defect. 
 
Minimal amount of area of the CSD was occupied by bone in 2 weeks in the control (2.12%) 
and E-matrixTM (5.08%) groups. In contrast to those values we observed a marked production 
of bone, covering 26.20% of the CSD, in the rhBMP-2 group. 
However, 40.21% which was reduced to 22.12% of the CSD was occupied by osteoid in the 
E-matrixTM group in the 4 and 6 weeks timeline respectively. Newly formed bone induced by 
rhBMP-2 filled almost exactly the same portion of the defect as that in the E-matrixTM group 
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for the same timelines. The corresponding areas of osteoid formed by the control group were 
consistently low to about one third of the value shown by the other two experimental groups. 
These values are graphically presented in table 4.2. 
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Table 4.2 Graphical representation of the average percentage of bone formation within the defect. 
 
RADIOGRAPHY
As with the histological analysis, we chose to include representative radiographs of each 
tested group in each of the three timelines. 
 
In the 2 week timeline, there is little to no evidence of bone formation in all groups (Fig. 10, 
11 & 12). Although some osteoid formation is suggested from the histomorphometric 
analysis in the rhBMP-2 group, it cannot be accounted for in the representative radiograph 
(Fig. 12). The radiopacity in all three radiographs at this stage are attributed to the DuraGen® 
scaffold. 
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Figure 10.  Control at 2 weeks.   Figure 11. EmatrixTM at 2 weeks.       Figure 12. rhBMP-2 at 2 weeks. 
At four weeks the DuraGen® scaffold appears to have been completely resorbed in the 
control group (Fig.13). In the E-matrixTM group (Fig.14), however, we can appreciate that a 
considerable area of the defect is occupied with osteoid/ woven bone especially around the 
periphery. Evidence of newly formed bone is present also in the rhBMP-2 group peripherally 
as well as centrally within the CSD. 
Figure 13. Control at 4 weeks.    Figure 14. E-matrixTM at 4 weeks.      Figure 15. rhBMP-2 in 4 weeks. 
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Finally, at six weeks new bone begins to form even in the control group but only peripherally 
(Fig.16). Comparable areas within the defect have been occupied with new bone both in the 
E-matrixTM and rhBMP-2 groups (Fig. 17 & 18). These areas are considerable larger than 
those in the control group and they are arranged in a centripetal fashion at the centre and 
periphery of the CSDs. 
Figure 16. Control at 6 weeks.        Figure 17. EmatrixTM at 6 weeks.         Figure 18. rhBMP-2 at 6 weeks. 
 
Due to errors in the measurement of the amount of bone formed in the defect area the MGV 
calculations thereof were discarded. 
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GOLDNER’S TRICHROME
This staining method was used to differentiate visually the areas of osteoid, woven and 
lamellar bone as well as collagen present in our specimens. Intense red denotes mineralized 
bone (woven or mature lamellar bone) and the light blue interprets areas of either osteoid 
(unmineralised bone matrix) or collagen which can be easily differentiated due to their 
distinct architecture. 
During the early stages of bone 
repair, we can appreciate the 
abundance of connective tissue with 
its wavy presentation (blue). There 
is very little osteoid and woven 
bone produced at this stage. 
 
 
 
Figure 19. Early stage in bone repair (2 weeks, control). 
 
Specimens showed a marked 
increase in the amount of new bone 
produced at 2 weeks in the rhBMP-
2 group. The trichrome staining 
confirmed the increased production 
of woven bone and showed 
evidence of osteoblastic rimming 
laying osteoid (blue) between them 
and the woven bone area. 
Figure 20. Early stage in bone repair (2 weeks, rhBMP-2). 
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In the later stages of bone repair 
there is a marked increase in the 
amount of woven bone containing 
osteocytes. Osteoblastic rimming is 
still evident by the presence of 
cuboidal cells next to actively 
forming area of osteoid (blue). 
 
 
Figure 21. Late stage of bone regeneration (6 weeks) (rhBMP-2). 
 
Consequently the newly formed 
bone acquired a more organized and 
mature architecture compared to the 
one present in the earlier stages of 
osteogenesis. Lamellar bone 
structure can be seen on the left side 
of this figure (Fig. 22). Haversian 
canals have also begun to form. 
 
Figure 22. Late stage of bone regeneration (6 weeks) (E-matrixTM). 
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DISCUSSION 
 
Re-examination of experimental design 
In this experimental model we assessed the potential of bone regenerative capability of a 
naturally derived polymer, E-matrix™ (porcine collagen + gelatin), on a true Critical Sized 
Defect (CSD) in rats. After 6 weeks of healing period, 22.12% of the original CSD area 
showed new bone formation whether it was treated with rhBMP-2 or our proprietary 
material, E-matrixTM. The histological results for E-matrix™ were particular encouraging 
with respect to the organization and quality of the newly formed bone. The latter appeared to 
be of highly comparable architecture to that seen in bone formation during repair process by 
secondary intention.  
The organization of the newly formed bone as it appeared on the histological examination as 
well as the potential biomechanisms that lead to its production will be discussed later in this 
chapter. 
It is worth noting the pattern of bone formation that transpired between the fourth and sixth 
week of observation irrespective of the type of treatment. There was a decrease in the area 
occupied by the newly formed bone. Such reduction can be explained by the physiology of 
bone remodeling. The resorptive phase of bone remodeling occurs between 
 
Carrier 
In our study we used a pre-formed disc-shaped synthetic collagen matrix (Duragen®, 
IntegraTM) as a supporting scaffold to deliver a novel hydrogel scaffold onto critical-size 
calvaria defects in rats. According to the manufacturer, DuraGen® has been predominately 
intended for dural defect closure and overall for neurological defect repair. Rabinowitz et al., 
(2005) studied the effect of this material by in vitro by culturing dissociated rat cerebral 
neurons on poly-L-lysin and cryostat-sectioned Duragen®. They concluded that DuraGen® 
has no adverse effects on the survival or process growth of neurons and thus it is safe to use 
as a dural substitute. In a comparative in vivo study in suboccipital craniotomy in humans 
between two alternative dural substitutes (DuraGen® and AlloDerm), Danish et al., (2006) 
concluded that both materials are acceptable scaffold materials with DuraGen® exhibiting 
much shorter healing time than AlloDerm. Cerebrospinal fluid containment was proved to be 
successful by Narotam and co-workers (2004). In a retrospective study of 110 patients that 
had undergone spinal dural repair and regeneration they concluded that cerebrospinal fluid 
containment was successful in over 95% of the cases. 
Although there was no macroscopic evidence of dural perforations during the rat surgeries in 
our experiment, the use of DuraGen® as our basic scaffold at least ensured effective closure 
against any accidental dural perforation and consequent possibility of CSF leakage. 
In addition in our study there was no histological evidence of any inflammatory reaction 
associated with DuraGen® and none of the tested subjects developed infection as a 
consequence of their treatment. Due to the type and site of induced experimental calvarium 
defect we felt that DuraGen® was the most appropriate semi-rigid scaffold. 
 
The scaffold material under investigation, E-matrixTM, belongs to the wider category of 
hydrogel scaffolds. Where solid scaffolds provide a substrate upon which cells may adhere, 
liquid and gel scaffolds function to physically entrap cells and osteogenic molecules 
(Elisseeff et al., 2005). 
Yet, researchers have been looking into modifying hydrogels in order to introduce adhesive 
properties to them. Nguyen et al., (2003), observed increased adherence of osteoblast-like 
Human Osteosarcoma (HOS) cells in vitro when inorganic bone mineral (ABM) particles 
coated with P-15 peptide (cell-binding domain of type-I collagen) (PepGenTM P15®, 
Ceramed) were suspended in injectable hyaluronate hydrogel. As a result of improved 
 42
adherence the following phenomena were observed: increased cell migration and cell 
coverage on the ABM surface; increase in the quantity and presence of stress fibers; 
enhanced gene expression which promoted considerable deposition of mineral matrix. In the 
work of Rowley and co-workers (1999), alginate was shown to have the potential of a model 
synthetic extracellular matrix when its properties were modified with the addition of RGD-
containing cell adhesion ligands. Alginate and other hydrogels are able to discourage protein 
adsorption due to the hydrophilic nature of their polymers. (Smentana, 1993). 
Passos-Bueno et al. (1999) utilizing a monolayer of hydrogel as a scaffold, cultured 
osteoprogenitor and MCS from mice with Apert Syndrome. Successful outcome suggested 
that in view of the cell behavior in the hydrogel the latter could be used to evaluate tissue 
development and potential therapeutic applications. Sweeney et al. (1995) noted that purified 
type I collagen gel matrix alone induced rapid and total CSD repair in rats. Reddi (2000) 
observed that type I collagen binds bone-promoting growth factors of the TGF family 
(including TGF-β and BMPs). This could mediate migration of osteoprogenitor cells into the 
defect, further promoting  osteogenic proliferation and differentiation. 
 
E-Matrix™ 
According to the manufacturers E-matrixTM is a biologically active co-polymer that 
stimulates fetal-like wound healing. E-Matrix is unique in its ability to promote this rapid, 
nearly scarless healing process normally found only in early fetal development. As a result, 
E-Matrix treatment rapidly heals chronic ulcers recalcitrant to other conventional and 
experimental treatments.  
E-Matrix Structure  
E-Matrix is a co-polymer of a high molecular weight protein and a high molecular weight 
carbohydrate designed to mimic early fetal mesenchymal connective tissue. This fetal 
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mesenchymal tissue is composed primarily of single stranded molecules as opposed to the 
triple stranded configuration found in the adult. The E-Matrix protein moiety is derived from 
triple stranded collagen extracted from adult porcine skin and processed into an open, 
monomeric single stranded form. In this monomeric configuration, polar binding sites are 
exposed that are unavailable in the native triple stranded configuration of adult collagen. This 
open configuration with exposed polar groups is maintained by co-polymerization with the 
high molecular weight carbohydrate. Enhancers are added to maintain this configuration 
during manufacture and storage.  
E-Matrix Mechanism of Action  
E-Matrix is a bioactive film that binds to host cells responsible for initiating the wound 
healing response. It is this physical interaction between E-Matrix and the host cells that 
initiates the wound healing cascade. Polar sites on the host cells are exposed through the 
disruption caused by the injection process and E-Matrix binds to these polar groups. In vitro 
studies with human fibroblasts have demonstrated E-Matrix binding to cell surfaces and the 
resultant cell aggregation. This interaction between E-Matrix and the cell surface in turn 
alters the gene expression of these cells. One of the genes that E-Matrix up-regulates is 
Transforming Growth Factor beta 3 (TGF beta 3), which is believed to be involved in the 
fetal-like wound healing response. It is hypothesized that the E-Matrix alteration of gene 
expression in appropriate host target cells activates the fetal-like wound healing response in 
treated wounds.  
Biological Effects of E-Matrix  
Fetal wound healing is characterized by an altered pattern of response compared to adult 
wound healing. Hallmarks of the fetal response include: a less tightly cross-linked extra-
cellular matrix; less differentiated cells in the wound bed; reduced wound contraction; rapid 
and sustained neo-vascularization; and scarless wound healing (Samuels and Tan, 1999). In 
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pre-clinical studies, E-Matrix has been shown to alter the type of extra-cellular matrix 
produced in the healed wound bed from a highly cross-linked, dense structure normally 
found in healed adult wounds to a more open reticular structure found in healed fetal wounds. 
E-Matrix treatment produces cells in the wound bed that are "mesenchymoid" in morphology 
and not the differentiated myofibroblasts typically seen in adults. As a result, there is less 
wound contraction as reflected by significantly reduced levels of the contractile protein actin 
(smooth muscle specific actin, SMSA) in the wound bed. E-Matrix also improves the 
vascularity in the injected areas and this vascular response is sustained in contrast to the 
transient increase in vascularization seen with growth factors. As a result of this fetal-like 
pattern of healing, wounds treated with E-Matrix heal with significantly reduced scarring and 
full integration of the tissue with existing host tissue. The tissue regeneration that results 
from E-Matrix treatment has now also been observed in patients with diabetic foot ulcers 
recalcitrant to other therapies  
Intellectual Property  
Encelle has developed a strong intellectual property position with respect to its technologies. 
Work to date has resulted in thirteen patents which have been issued and seven that are 
pending at the United States Patent and Trademark Office (USPTO).  
Patent applications claiming E-Matrix have been filed and are being prosecuted in all major 
markets (U.S., Europe, Japan, etc.). Filed claims include E-Matrix formulation, broad 
mechanisms of tissue regeneration, methods for increasing vascularization and promoting 
wound healing, and methods for medium and matrix for long-term proliferation of cells. 
 
Osseoinductive agents 
rhBMP-2 served in our experiment as the “gold standard” for bone formation. Originally this 
protein was identified as BMP-2A by Wozney et al., in 1988 and it possessed one tenth of 
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the bone-inductive potential of the pure native bovine protein when reconstituted with 
inactive, insoluble collagenous bone matrix and assayed ectopically in rats (Wang et al. 
1990). Since then rhBMP-2 were further modified and shown to stimulate in vitro the activity 
of alkaline phosphatase in bone marrow stromal cells (Thies et al., 1992). Other researchers 
showed in addition that rhBMP-2 stimulate pluripotent, non-osteogenic cells (Katagiri et al., 
1990) as well as cultured osteoblasts and osteoblast precursor cells which indicate the ability 
of the preparation to direct cell differentiation toward the osteoblast phenotype and the 
potential of genetically engineered rhBMP-2 to regenerate bone in vivo (Marden et al.).  
BMPs are the only known inductive agents. (Lind, 1996) and there is evidence that these 
molecules as well as TGF-β collaborate with to induce osteoblastic activity (Nguyen et al., 
2003). 
Concerns have been expressed with respect to increased dosages associated with the 
therapeutic effect of rhBMP-2. However, Poynton et al. (2003) defended the good safety 
profile and low systemic toxicity of BMP. It is worth noting that BMPs in general have a 
very high metabolic turnover and a half life of only few seconds once introduced to the 
defect site. 
The rapid metabolism of BMPs unveils the need for the prolonged presence of these 
molecules in the sites of desired bone regeneration. Schmoekel et al. (2004) showed the 
potency in induction of bone regeneration in a CSD in the rat calvarium with a prolonged 
BMP-2 retention achieved using a fibrin scaffold. BMPs bind to bone ECM by interaction of 
heparin-sulphate proteoglycan (Ruppert et al., 1996) and to collagen types II and IV (Sieron 
et al., 2002). This might be a valid consideration since we observed a rapid increase in the 
osteoid formation in our project in the rhBMP-2 group which was followed by a less 
prominent increase between the second and fourth week of observation. 
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 Type of defect 
The rat craniotomy defect is a convenient model for studying the bone regenerative potential 
of materials because of the ease of accessibility and the lack of requirement for fixation. 
CSD in this animal model are reproducible and have been tested in various in vivo studies  
 
Rats have an accelerated bone metabolism and are able to spontaneously regenerate 
proportionally greater bone defects than humans (Davies, 2000). Thus, the use of this model 
and especially of mature rats in bone engineering does not warrant transferability of healing 
patterns and overall results to human. In addition, due to reduced bone growth and 
remodeling in aging populations, successful tissue-engineering procedures observed on 
immature animal models does not reflect the osteogenic properties of the tested biomaterial 
in adults (Davies, 2000). 
 
Histological Results 
Although H&E staining was run for initial histological evaluation, Goldner’s Trichrome 
staining was selected as an additional histological assessment. This type of staining permitted 
the direct visualization of the areas occupied by osteoid and mineralized matrix which 
enhanced a crude observational assessment/ visualization of the amount of potentially new 
bone that was regenerated in our tested groups. 
Unfortunately, the possibility of using an alternative staining method (von Kossa) was not an 
option since all our initial histological specimens had been decalcified at an earlier stage. 
We found that it was essential to maintain the periosteum intact at the defect site in order to 
determine the exact dimensions of our CSD. The importance of this principle was also 
supported by Narang and Laskin (Davies, 2000). The presence or absence of the periosteum 
at the defect site is a key parameter when establishing the CSD for a particular animal model. 
The same authors showed that the size of a CSD on the fibula of Holtzman Albino rats 
 47
dropped from 12mm to 6mm when the periosteum was removed. They concluded that the 
presence of periosteum acted as a barrier to the defect site excluding its colonization by soft 
tissue and as a source of osteogenic MSCs thus promoting bone growth.  
 
Radiographical Analysis 
Assessment of bone formation on the radiographs using the Mean Gray Value (MGV) is 
inconsistent and unreliable. For the purposes of measuring the MGV the dura matter and the 
periosteum were left intact, defining the limits of the defect. However the similarity between 
their radiopacity and that of the newly formed bone, masked the areas of were bone was 
formed. 
Pryor et al., (2005) assessed the effect of PRP therapy in inducing bone formation utilizing a 
6.0mm diameter defect on rat calvaria. The assessment relied on radiographic observations of 
the specimens after 4 and 8 weeks of healing periods. The gross specimens were irradiated at 
70kVp, 7mA for 0.083 seconds allowing 12 inch distance between the specimen and the x-
ray source. The classification of the defects followed an elementary distinction in 3 groups 
based on 1. Non-closure, 2. Partial closure and 3. Complete closure of the defect area. The 
authors concluded that PRP preparation on ACS carrier had no significant effect on 
osteogenesis in their experimental model.  
Yet, such a radiographic analysis appears to be a relatively crude method of assessment of 
bone formation that might be used as an adjunct to histological analysis. To our opinion the 
use of radiography can be justified in our experiment to provide a general outlook to a novel 
material’s biological effect but not to draw final conclusions. 
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POTENTIAL MECHANISMS OF ACTION 
 
Signaling via cell transduction/ Osseoconduction 
Wilson-Hench (1987) suggested that osteoconduction is the process by which bone is 
directed to conform to a material’s surface. In osteoconduction bone grows on a surface. This 
definition requires the presence of a scaffold or osteoconductive surface onto which bone is 
allowed to grow. The safest way to determine if a substance is osteoinductive is to inject it at 
a heterotropic site and analyze any potential bone formation. 
Part of the reparative and remodeling process of skeletal tissue, which applies to our research 
model, is the early deposition of collagenous matrix. Subsequently, reparative cells from the 
defect borders migrate onto this matrix, organize and remodel the matrix through 
cytoskeleton and matrix synthesis/ degradation. Since the maintenance of the extracellular 
bone matrix is the primary goal of bone remodeling one can appreciate the importance of the 
presence of osteblasts and osteoclasts for the repair and homeostasis of the tissue. 
Equally important for the survival of most cell types is their anchorage to the scaffold as this 
is a strict requirement for several functions such as migration, proliferation, differentiation 
and apoptosis (Rowley et al., 1999). Thus, we can hypothesize that E-matrixTM possessed 
some inherent cell adhesion properties that potentially played a role in mediating and 
promoting recruitment of osteogenic cells (osteoconduction) from the defect’s tissue 
boundaries. 
 
Osseoinduction 
Osseoinduction is a process commonly encountered upon new bone formation. As a 
biological process it implies the recruitment of primitive, immature and undifferentiated cells 
and their stimulation to develop into preosteoblasts.  
BMP are the only known molecules with osseoinductive capacity and are released in 
response to trauma and bone remodeling (Ling, 1996). According to Frost (1989) the 
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inevitable injury sustained by the bone, marrow and soft tissue initiates the subsequent repair 
by sensitizing different types of surviving cells.  
The rational behind the use of this material is based on the notion that an unidentified 
compound/substance intrinsic to E-matrixTM is responsible for its osteogenic potential. 
 
Another possible speculation is that this material’s osseoinductivity may be due to its ability 
to modulate signaling pathways ultimately making cells more sensitive to osteogenic factors 
secreted in the defect area following trauma. Potentially the porcine collagen component in 
E-matrixTM can alter the activity of protein kinase C and increase cAMP level in response to 
parathyroid hormone (Nguyen et al., 2003). PTHrP and PTH are secreted as serum ionized 
calcium falls. Both hormones stimulate osteoclasts and rapid resorption by directly 
stimulating osteoblast action which then mediates the ostaoclastic activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Effect of Parathyroid Hormone (PTH) and Parathyroid Hormone Precursor (PTHrP) on the 
differentiation process of mesenchymal and osteoprogenitor cells. 
 50
A reduction/loss of bone was observed in the E-matrix group between the 4 and 6 week 
group. This is attributed to the physiology of bone healing. Bone physiology dictates that the 
resorptive phase of bone remodeling commences 3-4 weeks following insult to bone. 
 
VALIDITY OF THE MODEL 
We tested our novel material on an established critical size defect. Such defects have been 
defined as “defects that show less than 10% of bone healing within the life of the animal” 
(Hollinger & Kleineschmidt, 1990). Thus, the production of bone that covers more than 10% 
of the defect area proves the osseoinductive properties of the material. 
 
The rat as an animal model is an acceptable one for initial in vivo testing of a novel material 
and potential large number of subjects can be used for a valid statistical analysis.  
 
Our data suggest that E-matrixTM supports or promotes osteogenesis in the rat model. 
However the behavior of this material in large, space filling models e.g. tibia, mandible 
requires further investigation. 
 
E-matrixTM has been successful in human clinical trials for chronic skin wounds and has 
received FDA approval. Thus, it is poised for translational studies concerning bone repair. 
 
ADVANTAGES OF THE TECHNIQUE 
E-matrixTM is a synthetic material utilizing a denaturated, high MW protein derived from 
porcine skin and high MW carbohydrate. Due to its nature and method of manufacturing it 
has reduced risk of disease transmission. 
 
The material under investigation is biocompatible. There was no evidence in our histological 
analysis indicative of any adverse or inflammatory reaction associated with E-matrixTM. A 
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reason for this could be the naturally occurring polymers which in a denatured state may be 
relatively non-immunogenic. 
 
The cost effectiveness of using this material is marked. Compared to the considerable cost of 
using rhBMP-2 for its osseo-conductive properties, E-matrixTM provides an alternative 
therapeutic option at a twentieth of the cost of BMPs. 
 
E-matrixTM exhibits synergism when used with other scaffold material such as HA/TCP, 
anorganic bone and membranes. 
 
DISADVANTAGES OF TECHNIQUE 
E-matrixTM exists as a viscous gel in room temperature but its viscosity dramatically 
decreases at 38o C.  This physical property makes it a poor candidate for large, non-contained 
defects or areas that anatomically sustain increased loads, e.g. tibia. 
 
As seen on the histological slides there is no evidence of this material being present even 2 
weeks following its implantation. We speculated that E-matrixTM is resorbed 3-5 days after 
implantation to the defect side. Ideally such material should have a sustained presence within 
the defect for at least 2 weeks for more prominent bone formation. 
As this is the first in vivo study testing the osseoinductive properties of the material, it 
requires complete clinical documentation. 
Another disadvantage of this technique from a clinical application standpoint is the surgical 
intervention in order to deliver the osteogenic material. However, if used as an injectable 
material within a contained space this relative disadvantageous point can be eliminated. 
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POTENTIAL CLINICAL APPLICATIONS 
In the future, bone regeneration can be applied clinically where lack in bone mass can 
compromise or prohibit optimum treatment or when prognosis of final treatment is enhanced. 
Thus functional replacements for damaged or pathologic tissues can be made11 for example 
in recreating missing osseous structures (vertical bone loss), correcting craniofacial 
deformities and enhancing bone/tooth or bone/implant functionality and long-term stability12. 
E-matrixTM was tested to be successful in regenerating bone in a non-loading area, the 
calvarium. The most applicable clinical situation for this type of material with promising 
results and particular interest to us is the craniofacial region. Due to functional and 
anatomical differences the craniofacial skeleton is divided to upper and lower facial skeleton. 
Where the main function of the latter is primarily occlusal, the cranial portion exists as a 
static edifice protecting the brain and organs of special sense and providing a foundation for 
the attachment of the musculature and overlying soft tissue involved in facial expression and 
masticatory function. As a result of the distribution of muscle attachments in this area there is 
relatively little direct force of impact and significantly less direct muscular force applied to 
much of the upper facial skeleton. In addition, the constraining forces of the overlying soft 
tissues affect the net force on the facial skeleton and thus warrant special consideration  in 
that part of the skeleton where projection and fine contour are of significance (ch.50). Thus it 
is the restoration of the defects and asymmetries of the facial skeleton to their normal form 
that is the main goal of the craniofacial surgeon.  
At this stage it is important - for the success of the regeneration and reconstruction of the 
facial skeleton - to appreciate the need for a rigid scaffold in order for the latter to withstand 
the overlying soft tissue compressive forces. Biological requirements of the upper facial 
skeleton augmentation in particular dictate volume maintenance from the scaffold and the 
ability for it to be molded into the fine contours of the regional anatomy. Terheyden et al. 
reported the ectopic formation of mass tissue (mandible) using a mesh as a rigid scaffold and 
rhBMP-2 as his osseoinductive agent to regenerate a mandible. Once the bone tissue on the 
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graft was mature it was transferred to the recipient site. Maybe such mass tissue culture and 
transfers that requires the property of osseoinduction from the grafting components can be a 
possible niche for the application of our tested proprietary hydrogel in the future. 
 
The amount and quality of bone have been stated as some of the most important factors in the 
long term success of endosseous implants especially where augmentation procedures are 
required. Due to its potential superior performance in regenerating bone de novo this material 
can be considered in the application of alveolar ridge augmentation, sinus lift augmentation 
and even extraction site preservation following exodontia. 
 
LIMITATIONS 
One might also claim that there was no opportunity for osteoconduction due to the 
discrepancy between the defect size (8.9mm) and the scaffold size (8.0mm). Yet, the addition 
of the tested substances saline/hBMP-2 solution/Ematrix caused the collagen sponge to swell 
thus minimizing the distance between the implant and the margins of the defect. As a result 
of this there might have been no opportunity for osteoconduction between the borders of the 
defect and the grafted area due to the discrepancy between the defect size (8.9mm) and the 
scaffold size (8.0mm). 
 
All specimens collected for histological analysis were decalcified prior to being stained with 
Eosin and Haematoxylin. Thus no slides were available to be subjected to the Von Kossa 
staining method. Differentiation between mineralized mature bone, osteoid and collagen 
would have been clearer had we been able to use that method. VonKossa staining would have 
also negated the need for Goldner’s Trichrome staining. 
Unfortunately we did not dispose an adequate number of animals in this pilot study to be able 
to run any statistical tests with reliable results for the data we collected from the histological 
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analysis. At this point we relied on descriptive statistics (percentages) to essentially observe 
the trends associated with our results. 
 
The assessment of bone formation in the harvested calvaria areas via digital radiography and 
quantification using the Mean Grey Value (MGV) was problematic. The periosteum was left 
intact, defining the limits of the defect site, with only the soft tissues and brain matter being 
removed from the specimens. However, the radiopacity of the periosteum appeared to be 
similar to that of the newly formed bone, thus, masking the areas where new bone had been 
produced. For this reason we decided that the radiographic images would be used for the 
crude inspection of the area the new bone occupied in the defects. 
 
SUGGESTIONS FOR FUTURE RESEARCH 
One could propose to manufacture a cross-linked hydrogel in order to eliminate need for use 
of a rigid scaffold/ carrier. As a consequence this type of cross-linked/self-hardened/ 
photopolymerized scaffold will necessitate in vitro assessment to prove the lack of any 
harmful effects from the hardening process. 
Further projects will need to be undertaken to establish biocompatibility of our novel 
material to sustain adherence and growth of cultured stem cells when the later are intended, 
once expanded in culture, for delivery to the defect sites. Potentially the presence of adhesive 
peptides allows for a more natural environment for the anchorage-dependent osteoblast, 
hence, mineral deposition by the osteoblasts would be increased (Burdick & Anseth, 2002). 
 
To move a step forward towards the clinical application of such an osseoinductive material 
research need to be conducted on a higher primate animal model. In addition a larger number 
of subjects must be utilized to produce statistically significant results. 
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CONCLUSIONS 
 
Within the limitations of these experiments, the following can be concluded: 
(1) EmatrixTM induces bone formation in rat calvaria Critical-size defects. 
(2) The amount and histological appearance of the bone formed is comparable to that 
induced by rhBMP-2 over the same period of time. 
(3) Further clinical documentation is necessary to establish osseo-inductive properties of 
the material. 
  
 
APPENDICES 
 
 The statistical data presented in this study are numerical averages of the original data 
and their percentages. Considering the simplicity of these calculations there are no complex 
calculations to be presented in this section. 
 
A. IMAGE J ANALYSIS 
2 week group analysis 
 
TREATMENT GROUP SPECIMEN/ SLIDE NUMBER 
Control (DuraGen & saline) 1, 2 
EmatrixTM (DuraGen & EmatrixTM) 3,4,5 
rhBMP-2 (DuraGen & rhBMP-2) 6, 8 
 
 
 
 
Table A.1  Distribution of animals (their identifying number) into the experimental 
groups at 2 weeks. 
Image J area 
Animal section # of sections file number total 
area 
defect 
area 
% of 
bone 
per 
section 
Total % per 
animal 
1 a 1 P9070001 136829  0.61 0.35
   2 P9070001  829    
          
  b 1 P9070001 193264  0.00   
          0     
        
2 
only 
one 1 
e2w-2 only 
section 96141   3.88 3.88
   2 
e2w-2 only 
section  1039   
   3 
e2w-2 only 
section  1783    
   4 
e2w-2 only 
section  280    
   5 
e2w-2 only 
section  229    
   6 
e2w-2 only 
section  398    
          3729     
        
3 a 1 e2w-3a 185129   0.32 0.67
   2 e2w-3a  358    
   3 e2w-3a  120    
   4 e2w-3a  113    
      591    
          
  b 1 e2w-3b 68813  1.01   
   2 e2w-3b  438    
   3 e2w-3b  256    
          694     
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Image J area 
Animal section # of sections file number total area 
defect 
area 
% of 
bone 
per 
section 
Total % per 
animal 
4 a 1 e2w-4a 68308   21.50 10.8
   2 e2w-4a  7862    
   3 e2w-4a  2100    
   4 e2w-4a  1195    
   5 e2w-4a  1829    
   6 e2w-4a  1703    
      14689    
          
  b 1 e2w-4b 100864  0.10   
   2 e2w-4b  185    
   3 e2w-4b  93    
   4 e2w-4b  608    
   5 e2w-4b  122    
          1008     
        
5 a 1 e2w-5a 41820   4.65 3.77
   2 e2w-5a  690    
   3 e2w-5a  274   
   4 e2w-5a  979    
      1943    
          
  b 1 e2w-5b 71501  2.89   
   2 e2w-5b  794    
   3 e2w-5b  524    
   4 e2w-5b  214    
   5 e2w-5b  533    
          2065     
        
6 a 1 e2w-6a 152437   30.31 25.46
   2 e2w-6a  658    
   3 e2w-6a  5628    
   4 e2w-6a  1304    
   5 e2w-6a  28872    
   6 e2w-6a  8761    
   7 e2w-6a  978    
      46201    
          
  b 1 e2w-6b 159752  20.61   
   2 e2w-6b  227    
   3 e2w-6b  18617    
   4 e2w-6b  1205    
   5 e2w-6b  10069    
   6 e2w-6b  2807    
          32925     
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8 a 1 e2w-8a 207192   27.96 26.94
   2 e2w-8a  32269   
   3 e2w-8a  20732    
   4 e2w-8a  4925    
      57926    
          
  b 1 e2w-8b 177039  25.92   
   2 e2w-8b  13743    
   3 e2w-8b  13869    
   4 e2w-8b  18278    
          45890     
Table A.2  Area in the defect occupied by new bone calculated both in absolute values by 
“Image J” software and as percentages of the entire defect area at 2 weeks. 
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4 week group analysis
 
TREATMENT GROUP SPECIMEN/ SLIDE NUMBER 
Control (DuraGen & saline) 1, 2 
EmatrixTM (DuraGen & EmatrixTM) 3, 4, 5 
rhBMP-2 (DuraGen & rhBMP-2) 6, 7, 8 
 
 
 
 
 
 
 
Table A.3  Distribution of animals (their identifying number) into the experimental groups at 
4 weeks. 
 
 
 Image J area 
Animal Sections & file number new 
bone 
total 
defect 
% of 
bone in 
section 
Total % of 
bone in 
defect 
1 A 1 e4w-1a  70813 23.83 20.03
   2 e4w-1a 885     
   3 e4w-1a 123     
   4 e4w-1a 87     
   5 e4w-1a 61     
   6 e4w-1a 178     
   7 e4w-1a 357     
   8 e4w-1a 2776     
   9 e4w-1a 2108     
   10 e4w-1a 2414     
   11 e4w-1a 1852     
   12 e4w-1a 3624     
   13 e4w-1a 1683     
   14 e4w-1a 730     
     16878     
          
  B 1 e4w-1b  31953 16.22   
   2 e4w-1b 213     
   3 e4w-1b 122     
   4 e4w-1b 70     
   5 e4w-1b 1258     
   6 e4w-1b 652     
  
 
 
 
 
 
 
 
 
 
 
 7 e4w-1b 2867     
        5182       2 
only 
section 1 e4w-2   64679 0.00 0
        0       
3 
only 
sect 1 
e4w-3-only 
section   35862 36.23 36.23
    2 
e4w-3-only 
section 12993       
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4 A 1 e4w-4a   82264 22.55 21.70
   2 e4w-4a 13750     
   3 e4w-4a 988     
   4 e4w-4a 786     
   5 e4w-4a 263     
   6 e4w-4a 442     
   7 e4w-4a 2318     
     18547     
          
  B 1 e4w-4b  71784 20.84   
   2 e4w-4b 2889     
   3 e4w-4b 144     
   4 e4w-4b 3977     
   5 e4w-4b 7950     
        14960       
        
5 A 1 e4w-5a   63722 77.62 62.70
   2 e4w-5a 22672    
   3 e4w-5a 1360     
   4 e4w-5a 12660     
   5 e4w-5a 10931     
   6 e4w-5a 1835     
     49458     
          
  B 1 e4w-5b  69223 47.78   
   2 e4w-5b 5135     
   3 e4w-5b 386     
   4 e4w-5b 5296     
   5 e4w-5b 15885     
   6 e4w-5b 6373     
        33075       
        
6 A 1 e4w-6a   44848 34.82 54.89
   2 e4w-6a 8274     
   3 e4w-6a 1108     
   4 e4w-6a 713     
   5 e4w-6a 1741     
   6 e4w-6a 3780     
     15616     
          
  B 1 e4w-6b  40112 74.96   
   2 e4w-6b 9014     
   3 e4w-6b 3496     
   4 e4w-6b 2420     
   5 e4w-6b 239     
   6 e4w-6b 14898     
        30067       
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7 a 1 e4w-7a   96828 41.21 45.28
   2 e4w-7a 27678     
   3 e4w-7a 798     
   4 e4w-7a 12565     
   5 e4w-7a 3707     
     44748     
          
  b 1 e4w-7b  50449 49.35   
   2 e4w-7b 769     
   3 e4w-7b 3898     
   4 e4w-7b 318     
   5 e4w-7b 982     
   6 e4w-7b 4123     
   7 e4w-7b 8691     
   8 e4w-7b 6117     
        24898       
        
8 a 1 
e4w-8 only 
section   48181 27.67 27.67
   2 
e4w-8 only 
section 1025    
   3 
e4w-8 only 
section 815     
   4 
e4w-8 only 
section 7518     
   5 
e4w-8 only 
section 623     
   6 
e4w-8 only 
section 3353     
        13334       
Table A.4  Area in the defect occupied by new bone calculated both in absolute values by 
“Image J” software and as percentages of the entire defect area at 4 weeks. 
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6 week group analysis 
 
TREATMENT GROUP SPECIMEN/ SLIDE NUMBER 
Control (DuraGen & saline) 1, 6 
EmatrixTM (DuraGen & EmatrixTM) 3, 4, 5 
rhBMP-2 (DuraGen & rhBMP-2) 7, 8, 9 
Table A.5  Distribution of animals (their identifying number) into the experimental groups 
at 6 weeks. 
 
  Image J area Image J area 
  
Sections new 
bone 
total 
defect 
Sections new 
bone 
total 
defect 
Animal 1   E6w-1a   173336   E6w-1b   131876
  2 E6w-1a 238  2 E6w-1b 175   
  3 E6w-1a 689  3 E6w-1b 108   
  4 E6w-1a 23459  4 E6w-1b 57   
  5 E6w-1a 373  5 E6w-1b 487   
  6 E6w-1a 162    827   
  7 E6w-1a 189       
     25110       
            
  % of bone   14.49       0.63 7.56
         
Animal 3   E6w-3a   281035   E6w-3b   225474
  2 E6w-3a 201  2 E6w-3b 211   
  3 E6w-3a 11892  3 E6w-3b 278   
  4 E6w-3a 1013  4 E6w-3b 4021   
  5 E6w-3a 1047  5 E6w-3b 336   
  6 E6w-3a 52149  6 E6w-3b 85   
  7 E6w-3a 2122  7 E6w-3b 1173   
  8 E6w-3a 320  8 E6w-3b 4243   
  9 E6w-3a 11016  9 E6w-3b 808   
     79760  10 E6w-3b 1086   
         12241   
  % of bone   28.38       5.43 16.905
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Animal 4   E6w-4a   325345   E6w-4b   259758
  2 E6w-4a 1665  2 E6w-4b 11346   
  3 E6w-4a 423  3 E6w-4b 3958   
  4 E6w-4a 44908  4 E6w-4b 426   
  5 E6w-4a 27586  5 E6w-4b 2759   
  6 E6w-4a 39896  6 E6w-4b 266   
  7 E6w-4a 35229  7 E6w-4b 139   
  8 E6w-4a 408  8 E6w-4b 7854   
     21445  9 E6w-4b 263   
       10 E6w-4b 39194   
       11 E6w-4b 19432   
         85637   
            
  % of bone   6.59       32.97 19.78
         
Animal 5   E6w-5a   216494   E6w-5b   162448
  2 E6w-5a 65804  2 E6w-5b 455   
  3 E6w-5a 3999  3 E6w-5b 1669   
  4 E6w-5a 4882  4 E6w-5b 500   
  5 E6w-5a 912  5 E6w-5b 812   
  6 E6w-5a 41177  6 E6w-5b 291   
     116774  7 E6w-5b 5045   
         8772   
            
  % of bone   53.94       5.4 29.67
         
         
Animal 6   E6w-6a   187484   E6w-6b   155278
  2 E6w-6a 1416  2 E6w-6b 373   
  3 E6w-6a 968  3 E6w-6b 219   
  4 E6w-6a 139  4 E6w-6b 12124   
  5 E6w-6a 2037  5 E6w-6b 708   
     4560  6 E6w-6b 2970   
       7 E6w-6b 1262   
       8 E6w-6b 8172   
         25828   
            
  % of bone   2.43       16.63 9.53
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Animal 7   E6w-7a   196829   E6w-7b   171421
  2 E6w-7a 701  2 E6w-7b 150   
  3 E6w-7a 15026  3 E6w-7b 8239   
  4 E6w-7a 10220  4 E6w-7b 6906   
     25947  5 E6w-7b 289   
       6 E6w-7b 468   
       7 E6w-7b 5636   
         21688   
            
  % of bone   13.18       12.65 12.915
         
         
Animal 8   E6w-8a1   226949   E6w-8b2   196007
  2 E6w-8a1 11778  2 E6w-8b2 49785   
  3 E6w-8a1 434  3 E6w-8b2 3463   
  4 E6w-8a1 439  4 E6w-8b2 3580   
  5 E6w-8a1 1901  5 E6w-8b2 1029   
  6 E6w-8a1 1002  6 E6w-8b2 3082   
  7 E6w-8a1 401  7 E6w-8b2 723   
  8 E6w-8a1 35035  8 E6w-8b2 535   
  9 E6w-8a1 559  9 E6w-8b2 1433   
  10 E6w-8a1 175  10 E6w-8b2 10378   
  11 E6w-8a1 2782  11 E6w-8b2 616   
  12 E6w-8a1 592  12 E6w-8b2 9324   
  13 E6w-8a1 2394    83948   
  14 E6w-8a1 22775       
     80267       
            
  % of bone   35.37       42.83 39.1
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Animal 9   E6w-9a1   186788   E6w-9b2   199463
  2 E6w-9a1 26387  2 E6w-9b2 1307   
  3 E6w-9a1 6094  3 E6w-9b2 10123   
     32481  4 E6w-9b2 598   
       5 E6w-9b2 1276   
       6 E6w-9b2 71   
       7 E6w-9b2 1024   
       8 E6w-9b2 69   
       9 E6w-9b2 93   
       10 E6w-9b2 288   
       11 E6w-9b2 2527   
       12 E6w-9b2 274   
       13 E6w-9b2 3648   
       14 E6w-9b2 305   
       15 E6w-9b2 138   
       16 E6w-9b2 553   
       17 E6w-9b2 173   
         22467   
            
  % of bone   17.39       11.26 14.325
Table A.6  Area in the defect occupied by new bone calculated both in absolute values by 
“Image J” software and as percentages of the entire defect area at 6 weeks. 
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